(Updates with information from a briefing released by FDA regarding the upcoming review of the company’s DMD drug) Sarepta Therapeutics ( SRPT ) shares were down 54% Friday as the U.S. Food and Drug Administration demonstrated skepticism as to
Update: Sarepta Therapeutics Plummets on Muted FDA Briefing Ahead DMD Drug Review
